MarketResearchNest.com adds “Hyperuricemia – Pipeline Review, H2 2017” new report to its research database. The report spread across 60 pages with table and figures in it.
Hyperuricemia – Pipeline Review, H2 2017
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia – Pipeline Review, H2 2017, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.
High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.
Browse full table of contents and data tables at
https://www.marketresearchnest.com/hyperuricemia—pipeline-review-h2-2017.html
The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 4, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Involved in Therapeutics Development
Allena Pharmaceuticals Inc, AstraZeneca Plc, CymaBay Therapeutics Inc, Nippon Chemiphar Co Ltd, Nobelpharma Co Ltd, Polaris Pharmaceuticals Inc, Teijin Pharma Ltd.
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=262560
Featured News & Press Releases
Apr 21, 2017: Mylan Receives CHMP Positive Opinion For Febuxostat
Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit
Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricaemia and Predicts Savings for NHS Scotland
May 23, 2016: Teijin Pharma’s Feburic (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia
Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 – 11
Jun 30, 2015: New Indication for Teijin Pharma’s Febuxostat in Europe
Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat
Nov 05, 2013: Teijin Pharma files patent infringement suit against Dr Reddy’s
Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric
Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat
Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat
Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea
May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan
Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67
Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a sample copy at
https://www.marketresearchnest.com/requestsample.php?reportid=262560
About Us:
MarketResearchNest.com is the most comprehensive collection of market research products and service Hyperuricemia on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Contact Us
Mr. Jeet Jain
Sales Manager
+1-240-284-8070(U.S)
+44-20-3290-4151(U.K)
Your information will never be shared with any third party.